Artiva Biotherapeutics, Inc. Common Stock (ARTV) Stock Price
ARTVStock
$11.09+250.95%52W
Market Cap$542.19M
P/E—
PEG Ratio—
Div yield—
Beta5.49
ARTV Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)108.99%
Price vs S&P 500 (4W)1.53%
VGM Score93.70
ARTV Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.64 | -$0.63 | +1.95%(+$0.01) | |
| Q1 2026 | -$0.84 | -$0.95 | -12.65%(-$0.11) | |
| Q4 2025 | -$0.80 | -$0.84 | -5.00%(-$0.04) | |
| Q3 2025 | -$0.80 | -$0.88 | -10.00%(-$0.08) | |
| Q2 2025 | -$0.77 | -$0.87 | -12.99%(-$0.10) |
ARTV Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.25
4.25
4.25
4.25
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ARTVArtiva Biotherapeutics, Inc. Common Stock | — | — | A | $11.09 |
| AMGNAmgen Inc | C | C | B | $432.42 |
| GILDGilead Sciences Inc | C | B | B | $145.68 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1023.21 |
| MRNAModerna, Inc. Common Stock | D | C | A | $137.99 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $207.88 |
| BIIBBiogen Inc. Common Stock | C | D | B | $218.50 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $102.08 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $154.06 |
| EXELExelixis Inc | C | B | B | $54.45 |
| HALOHalozyme Therapeutics, Inc. | C | B | B | $105.35 |
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics develops allogeneic NK cell therapies designed to treat hematologic malignancies and solid tumors. The company's lead program, AlloNK, is an off-the-shelf, cryopreserved NK cell therapy engineered to enhance the antibody-dependent cellular cytotoxicity of monoclonal antibodies. Its pipeline also includes CAR-NK cell candidates (AB201 and AB205) supported by both internal and collaborative funding.